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Performance status (PS) is the assessment of patients’ actual level
of function and capability of self-care, usually recorded by health
professionals using a traditional scoring system such as the
Karnofsky scale (Karnofsky et al, 1948) or the Eastern Cooperat-
ive Oncology Group (ECOG) scale (Oken et al, 1982). PS has
repeatedly been demonstrated to be an important prognostic factor
for survival in several major malignancies such as breast cancer
(Aisner et al, 1995), ovarian cancer (Lund et al, 1990), small cell
lung cancer (Osterlind and Andersen, 1986), and non-small cell
lung cancer (Paesmans et al, 1995). Accordingly, it must be taken
into consideration in the planning and evaluation of clinical trials
of cancer treatment and in the decision on therapeutic options in
clinical practice. The subjective view associated with the determi-
nation of PS, however, is also well acknowledged (Loprinzi et al,
1994), and there is no ‘gold standard’ method for the assessment
of PS (Schag et al, 1984). Previous studies demonstrated that the
inter-observer agreement was only moderate among health profes-
sionals such as nurses, social workers, psychiatrists, and oncolo-
gists (Hutchinson et al, 1979; Schag et al, 1984; Taylor et al, 1999;
Yates et al, 1980). 
Conflicting results have been reported by several studies on inter-
observer agreement in grading PS between the patients themselves
and the oncologists. A previous study, for example, suggested that
the PS assessment by the physicians specialized in clinical oncology
was healthier than that by the patients (Loprinzi et al, 1994).
However, the result might be biased because the patients had already
been assessed by the physicians as chemotherapy-tolerable before
participating in simultaneous chemotherapy trials. On the contrary,
another small pilot study reported that the patients rated themselves
as healtheir than the oncologists did (Taylor et al, 1999). Since
patients are supposed to know their own physical condition better
than anyone, the assessment of PS by the patients themselves would
be reasonable and might be more reliable for prediction and stratifi-
cation of prognosis. Indeed, recent studies on quality of life have
suggested that the information from patient-completed question-
naires could be a prognostic factor independent of PS assessed by
the physicians (Coates et al, 1992; Cella et al, 1997). Thus, if there
are non-chance discrepancies in the assessments of PS among
patients and external observers, the assessment of PS by health
professionals should be rationalized by an advantage for prediction
and stratification of patients’ survival. 
We, therefore, planned to investigate whether there was any
systematic difference among the assessment of PS by patients
themselves, nurses, and oncologists. To elucidate which of the
three assessments would be the most useful prognostic factor, we
prospectively examined PS of patients with recently diagnosed
non-small cell lung cancer and evaluated the prognostic value of
each assessment. 
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MATERIALS AND METHODS 
Patients 
Between January 1995 and November 1998, consecutive inpatients
with pathologically confirmed non-small cell lung cancer were
prospectively accrued at Japanese Red Cross Nagoya First Hospital,
a university-affiliated educational hospital with almost 1000 beds.
To be eligible for this study, patients had to have stage III or IV
disease at the initial staging procedure described below. Of 209
patients who were eligible, 3 refused to enter the study because of no
interest in participation. This study had at least 85% statistical power
to detect the 15% difference in the proportions of patients assessed
as ECOG PS 0 to 1 (estimated proportions, 55% for patients them-
selves, 70% for oncologists) at the 5% significance level. This study
was approved by the Institutional Review Board, and participants
gave written informed consent before they entered the study. 
Performance status assessment 
The patients were asked to complete a short questionnaire
regarding their own assessment of ECOG PS (Oken et al, 1982) as
soon as after the diagnosis of lung cancer (Table 1). The question-
naire was delivered to each patient by a ward clerk to be filled out
by the patient at the bedside. When the patient was unable to fill
out the questionnaire by himself/herself, the clerk read it aloud and
wrote down the patient’s answer given orally. The clerk did not
provide any specific implication of the terms in the questionnaire
that might cause bias in the final interpretation of each PS descrip-
tion. Simultaneously, the attending oncologist and nurse working
on the ward assessed the patient’s ECOG PS in separate rooms of
the ward by completing each questionnaire which included the
same description of PS as shown in Table 1. The completed ques-
tionnaires were sealed in envelopes by each respondent before
being turned in to the responsible investigator of this study (MA).
Thus, each observer was blinded to the ratings of the others. The
nurses and oncologists, who were dedicated to the care of patients
with lung cancer, received no special training for participation in
this study because they were familiar with the assessment of PS in
daily oncology practice. They were asked not to interview the
patients solely for assessment of PS, but to use the information
they had obtained during the patient’s care. All the oncologists
were members of the Japan Lung Cancer Society. 
Staging procedures 
Patients were staged according to the TNM system (Mountain,
1997). Patients underwent the following procedures on the initial
presentation: medical history, physical examination, histologic or
cytologic confirmation of non-small cell lung cancer, complete
blood cell counts with differential, serum chemistry, chest radi-
ograph and computed tomography (CT), abdominal CT and/or ultra-
sonography, brain CT, and radionuclide bone scan. Bone radiographs
were used to confirm metastatic lesions suspected by bone scan. 
Demographic and clinical factors 
Besides PS assessments by patients, nurses, and oncologists, the
following potential prognostic factors were evaluated: age, gender,
histology, metastatic organs (brain, liver, bone, lung, and lymph
node), disease stage, T factor, N factor, weight loss within 6
months, leukocyte count, neutrophil count, platelet count, haemo-
globin, serum albumin, serum lactate dehydrogenase (LDH), and
the treatment modality (chemoradiotherapy, chemotherapy, radio-
therapy, or supportive care alone). 
Statistical methods 
The proportions of patients assessed as fully ambulatory (PS 0 or
1) by the patients themselves and the oncologists were compared
by chi-square test. The inter-observer agreement in the assess-
ment of PS was evaluated using simple and weighted Kappa
statistics (Cohen, 1960, 1968). In order to identify the predictor
of disagreement in the PS assessment between the patients them-
selves and the oncologists, a multivariate logistic regression
analysis was performed (Breslow and Day, 1980). In this
analysis, the following variables were investigated for associa-
tion with the proportion of patients whose assessment agreed
with that of the oncologists: age, gender, weight loss, disease
stage, treatment modality, and attending oncologist. Friedman
test and Mann-Whitney U-test were used to compare the assess-
ments of PS by the three groups and to compare each of the three
pairs of assessments, respectively. Because elderly patients are
generally excluded from clinical trials of cancer treatment, we
examined whether the results of these comparisons remain
unchanged when patients over 75 years old were excluded from
the study population. Survival was calculated from the day of
pathological diagnosis until death. Patients alive were censored
as of last known follow-up. Survival curves were calculated
using Kaplan-Meier method and compared using log-rank test.
Prognostic importance of the factors including PS assessed by
the three groups was analyzed using the Cox regression model
(Cox, 1972). Forward stepwise procedures were used to select
factors that were included in the final model. A-2 log likelihood
value for fitting a model with all the explanatory variables was
Table 1 Patient questionnaire for the determination of their ECOG PS 
Please circle the number of the phrase which characterizes you best at this time, according to your own
judgement. Please do not ask advice from any others 
0 Fully active, able to carry on all pre-disease performance without restriction 
1 Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary
nature, e.g., light house work, office work 
2 Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than
50% of waking hours 
3 Capable of only limited self-care, confined to bed or chair more than 50% of waking hours 
4 Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair 
ECOG, Eastern Cooperative Oncology Group; PS, performance status. 1636 M Ando et al
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calculated for individual Cox models which included patient-,
nurse-, and oncologist-assessed PS separately, and was used to
compare the performance of these three models. The likelihood
ratio test was used to examine whether the fit of model including
oncologist-assessed PS, which proved to be the best performing
model in the present study, could be further improved by addi-
tional inclusion of the PS scores by the patients or the nurses.
Statistical analyses were performed by SAS ver. 6.12 software
(SAS Institute Inc., Cary, NC). 
RESULTS 
Characteristics of the 206 patients who entered the study were
presented in Table 2. Age of the subjects was 67 ± 10 (mean ± SD)
years old. No patient was lost to follow-up, and 16 patients alive
were censored. The median follow-up time in the 16 patients was
824 days (range 352–1296). 
Twelve oncologists and 45 nurses participated in the assessment
of PS. The distribution of the assessments by the patients them-
selves and the health professionals are shown in Tables 3 and 4.
The oncologists assessed 71% of patients as ECOG PS 0 or 1,
while 59% of the patients rated themselves as ECOG PS 0 or 1
(P = 0.007). The simple and weighted Kappa statistics between the
two assessment were 0.29 (95% confidence interval 0.20–0.39)
and 0.53 (95% confidence interval 0.45–0.61). The two Kappa
values were 0.45 (95% confidence interval 0.36–0.55) and 0.63
(95% confidence interval 0.54–0.71) between the nurses and the
oncologists, and 0.38 (95% confidence interval 0.28–0.47) and
0.56 (95% confidence interval 0.48–0.64) between the patients and
the nurses, respectively. Thus, the best agreement was observed
between nurse- and oncologist-assessed PS irrespective of the
Kappa statistics used. In multivariate logistic regression analysis,
only gender was significantly correlated with the disagreement in
the PS assessment between the patients themselves and the oncol-
ogists (P = 0.037); the level of agreement was lower in female
patients (37.2%) than in male patients (54.0%). The proportion of
patients whose assessment of PS was poorer than that by the
oncologists was 51.2% in females and 31.3% in males (P = 0.015). 
A systematic difference in the assessments of PS was observed
among the three groups (P < 0.001); assessment by oncologists
Table 2 Demographic and clinical variables of patients 
Number of patients Median
Total Patient-assessed PS (%) Nurse-assessed PS (%) Oncologist-assessed PS (%)  survivala
0–1 2–4 0–1 2–4 0–1 2–4 
(days)
Gender 
female 43 21 (49) 22 (51) 27 (63) 16 (37) 29 (67) 14 (33) 245 
male 163 100 (61) 63 (39) 116 (71) 47 (29) 118 (72) 45 (28) 210 
Weight loss within 6 months 
< 5% 115 83 (72) 32 (28) 95 (83) 20 (17) 100 (87) 15 (13) 280 
5–10% 46 22 (48) 24 (52) 27 (59) 19 (41) 26 (57) 20 (43) 181 
≥ 10% 45 16 (36) 29 (64) 21 (47) 24 (53) 21 (47) 24 (53) 90 
Disease stage 
IIIA 34 26 (76) 8 (24) 31 (91) 3 (9) 30 (88) 4 (12) 463 
IIIB 85 53 (62) 32 (38) 58 (68) 27 (32) 62 (73) 23 (27) 255 
IV 87 42 (48) 45 (52) 54 (62) 33 (38) 55 (63) 32 (37) 106 
Histology 
squamous cell carcinoma 84 55 (65) 29 (35) 63 (75) 21 (25) 63 (75) 21 (25) 244 
adenocarcinoma 108 61 (56) 47 (44) 72 (56) 36 (44) 77 (71) 31 (29) 216 
large cell carcinoma 14 5 (36) 9 (64) 8 (57) 6 (43) 7 (50) 7 (50) 66 
Treatment 
chemoradiotherapy 31 28 (90) 3 (10) 30 (97) 1 (3) 30 (97) 1 (3) 476 
chemotherapy 55 41 (75) 14 (25) 47 (85) 8 (15) 51 (93) 4 (7) 255 
radiotherapy 20 11 (55) 9 (45) 13 (65) 7 (35) 13 (65) 7 (35) 198 
supportive care 100 41 (41) 59 (59) 53 (53) 47 (47) 53 (53) 47 (47) 96 
aMedian survival was calculated after exclusion of four patients with previous malignancy. 
PS, performance status. 
Table 3 Agreement in assessment of ECOG PS between patients and
oncologists (n = 206) 
Oncologist’s Patient’s score 
score
012 3 4  
01 7 2 2 0 0 0  
11 3 6 3 2 3 8 1  
21 3 6 1 2 2  
30 1 4 1 1 5  
40 1 0 6 7  
ECOG, Eastern Cooperative Oncology Group; PS, performance status. 
Table 4 Agreement in assessment of ECOG PS between patients and
nurses (n = 206) 
Nurse’s Patient’s score 
score
01 2 3 4  
01 5 1 2 0 0 0  
11 4 7 1 1 9 1 0 2  
22 5 8 8 0  
30 2 6 1 7 6  
40 0 0 2 7  
ECOG, Eastern Cooperative Oncology Group; PS, performance status. was the healthiest, that by nurses was intermediate, and that by
patients themselves was the poorest. Assessments by oncologists
and nurses were both significantly healthier than that by patients
themselves (P < 0.001 and P = 0.003, respectively). On the other
hand, there was no significant difference in the assessment
between nurses and oncologists (P = 0.137). Difference among the
three assessments remained significant when female and male
patients were analysed separately (P < 0.001 and P = 0.004,
respectively). The systematic difference remained significant
when 23 patients over 75 years old were excluded (P < 0.001),
with healthier assessments by oncologists and nurses than those by
patients (P < 0.001 and P = 0.005, respectively). 
In survival analysis, 4 patients with previous malignancy were
excluded. Median survival time of the resultant 202 patients was 221
days. Survival curves according to PS graded by patients and oncolo-
gists are shown in Figure 1. In univariate analyses, PS assessments by
patients, nurses, and oncologists were all significantly correlated
with survival (P < 0.001 in all cases). However, survival curves of
patients with PS 1 and 2 by their own assessment were superim-
posed until 600 days after diagnosis. When included separately in
the Cox model, each of the three PS assessments was significantly
correlated with survival (Table 5). Gender, weight loss, haemo-
globin, disease stage, T factor, bone metastasis, and treatment
modality were selected as covariates in every case. In addition,
lymph node metastasis was selected as a covariate when nurse- or
oncologist-assessed PS was incorporated into the model. Because
the selected factors were almost the same across the three models,
we used all these factors as covariates for which the adjustment
was carried out. The –2 log likelihood values with all the explana-
tory variables were 1494.4, 1502.2, and 1488.2 for the Cox models
including patient-, nurse-, and oncologist-assessed PS, respec-
tively. Since the degrees of freedom were the same among the
three models, these results indicated that the Cox model including
oncologist-assessed PS best fitted to the observed survival data.
Performance status by patients and health professionals 1637
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Table 5 Prognostic value of ECOG PS graded by patients, nurses, and oncologists: results of analyses separately included
in the Cox model 
Multivariate-adjusted hazard ratiosa (95% CI) 
Variables Patient-assessed PS Nurse-assessed PS Oncologist-assessed PS 
PS Score 
0 reference reference reference 
1 1.63 (0.97–2.83) 1.79 (1.07–3.12) 1.63 (1.04–2.64) 
2 1.60 (0.89–2.93) 2.08 (1.06–4.13) 1.95 (1.00–3.79) 
3 2.77 (1.46–5.33) 2.25 (1.15–4.49) 4.28 (2.23–8.10) 
4 3.90 (1.81–8.25) 2.99 (1.18–7.16) 3.43 (1.61–7.07) 
P-trend < 0.001 0.018 < 0.001 
aIn each model, adjustment was made for gender, weight loss, haemoglobin, T factor, lymph node metastasis, bone
metastasis, disease stage, and treatment modality. 
ECOG, Eastern Cooperative Oncology Group; PS, performance status; CI, confidence interval. 
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Figure 1 Kaplan-Meier plots of survival of patients with advanced non-small cell lung cancer, divided by the assessment of performance status (A) by the
patients themselves and (B) by the oncologists 1638 M Ando et al
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The fit of this oncologist-assessed PS model was not significantly
improved by additional inclusion of categorical variables indi-
cating the PS scores by the patients or the nurses 
(P = 0.374 and P = 0.339, respectively). 
DISCUSSION 
The present study demonstrated that the assessments of PS by
health professionals, i.e., nurses and oncologists, were systemati-
cally different from that by the patients themselves. This finding
may be relevant to previous reports that observer ratings of
patients’ quality of life were different from those of the patients
themselves (Presant, 1984; Slevin et al, 1988; Osoba, 1994).
Assessments of PS by nurses and oncologists were found to be
healthier than that by the patients themselves. Furthermore, the
agreement in the PS assessment between the two health profes-
sionals was better than that between the patients and the health
professionals. These results may suggest that the tendency to rate
healthier PS was not peculiar to the oncologists but also true of
other health professionals. The difference in the PS assessment
remained significant when the analyses were limited to younger
patients who are considered potentially suitable for clinical trials.
We, therefore, consider that the problem of discrepancy in the
assessment of PS would be relevant in judging eligibility for clin-
ical trials. 
Investigations of the predictor variables of inter-observer
disagreement are scarce in the PS assessment, although a similar
analysis was conducted in the assessment of quality of life in
cancer patients (Sneeuw et al, 1999). Interestingly, the results of
the present study showed that female patients had a lower level of
agreement in the PS assessment between the patients and the
oncologists. The female patients reported poorer PS of their own
compared with the male patients. Only two female oncologists
assessed PS of 22 patients in our study, and this small number
precluded detailed analysis of the gender-related difference.
However, a similar difference was reported in other studies on
quality of life in the general population (Brazier et al, 1992;
Jenkinson et al, 1993; Hjermstad et al, 1998). In these studies,
females reported poorer health status, including physical well-
being, than males. In addition to the results in these ‘reference
population’, female patients with asthma were shown to report
worse physical and social status than male patients (Osborne et al,
1998), which warrants further studies to investigate whether this
gender-related difference is also observed in patients with other
chronic diseases. 
Oncologist-assessed PS has traditionally been used as a criterion
in clinical trials, which is partly supported by an acceptable level
of agreement among the assessments by oncologists, especially for
patients in good physical condition (Conill et al, 1990; Roila et al,
1991; Sørensen et al, 1993). This is the first study investigating
whether the assessment of PS by the oncologists is rationalized in
terms of the prognostic value. Univariate and multivariate analyses
demonstrated that the assessment of PS 0, 1, and 2 by oncologists
successfully stratified survival, whereas that by the patients them-
selves failed to distinguish survival of patients with PS 1 and 2. It
would be critical to stratify patients for clinical trials in which only
fully ambulatory patients should be the candidates (Bonomi et al,
1991; Ihde, 1992; Shepherd, 1994). Furthermore, the Cox model
including oncologist-assessed PS best fitted to the observed
survival data as indicated by the lowest -2 log likelihood value.
These advantages for prediction and stratification of prognosis
provided additional support for the use of the assessment of PS by
oncologists in clinical trials for advanced non-small cell lung
cancer. Because one reason for restriction on the entry of patients
with PS 2 onto clinical trials were their poor tolerability of treat-
ment (Ruckdeschel et al, 1986), further work will be needed to
determine whether oncologist-assessed PS is also more reliable in
predicting treatment-related toxicities than patient-assessed PS. 
The present study showed that the straightforward assessment of
PS by the patients themselves is not a fruitful method, because the
assessment by the patients failed to demonstrate a better prog-
nostic value than that by the oncologists. Although Loprinzi et al
suggested that patient-assessed PS could provide independent
prognostic information in their study, the ability of the Cox model
to explain the data did not change substantially even when PS
assessed by patients themselves was included in or excluded from
the model (Loprinzi et al, 1994). In addition, the poorest model in
their study was the one that did not include oncologist-assessed
PS. These results suggest that the prognostic importance of PS
assessment by patients themselves does not exceed that by oncolo-
gists. This advantage in assessment by oncologists in the estima-
tion of prognosis might be partly explained by the availability of
information from observation and examination of the patient
(Schag et al, 1984). Considering the problem of colinearity among
the PS assessments, prognostic importance of the combination
indices of these assessments may be worthy of exploration. 
In conclusion, the assessment of PS by the patients themselves
is different from the assessments by health professionals such as
nurses and oncologists. Assessments by the oncologists and the
nurses were significantly healthier than that by patients them-
selves. However, this does not imply that health professionals
would be optimistic and patients pessimistic and it is not possible
to say who is correct. This might be an unconscious appeal for
comfort or care from patients toward health professionals. Rather,
this suggests that the assessments by health professionals would
predict patients’ prognosis more precisely than that by the patients
themselves. Our results reinforced the rationale for the traditional
use of oncologist-assessed PS in clinical oncology, and supported
treatment decisions based on oncologists’ assessment of PS. 
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